id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303232-0lwmzjxz	Konig, Maximilian F	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome	2020-04-08		.txt	text/plain	1433	81	38	The mortality of Coronavirus disease 2019 (COVID-19) appears to be driven by acute respiratory distress syndrome (ARDS) and a dysregulated immune response to SARS-CoV-2. Emerging evidence suggests that a subset of COVID-19 is characterized by the development of a cytokine storm syndrome (CSS), and interleukin (IL)-6 levels are predictors of COVID-19 severity and in-hospital mortality. As high infection rates threaten to overwhelm hospital capacity during this pandemic, preventative approaches that ameliorate COVID-19 severity and reduce excessive mortality are desperately needed. We hypothesize that treatment with prazosin of individuals who test positive for SARS-CoV-2 could reduce catecholamine surges, secondary cytokine dysregulation, and mortality. Prospective, randomized clinical trials of alpha-1 receptor antagonists (e.g. prazosin) administered prior to the onset of severe symptoms are needed to assess their efficacy in preventing CSS and reducing mortality in COVID-19. Prospective, double-blinded clinical trials of ⍺1-AR antagonists in high-risk patients, when administered prior to symptom onset, will therefore be required to assess their utility in preventing COVID-19-CSS.	./cache/cord-303232-0lwmzjxz.txt	./txt/cord-303232-0lwmzjxz.txt